-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25

Benzinga·08/03/2026 19:46:53
Listen to the news
UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.